Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 61.97

-3.2%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (16748)	5/11/2005 10:06:59 AM
From: former_pgs	Read Replies (2) of 52153

Some additional color on phenoxodiol's results The company used RECIST criteria to measure responses in the interim analysis. I initially wondered if they had used CA-125 as their previous PRs had referred to this tumour marker and not actual tumour shrinkage. The responses were independently evaluated, so that's always a plus. There were 27 evaluable patients within this group of 40. A little sloppy on their part not to mention this. Nonetheless, that leaves us with 3 complete responses and 6 partial responses. One hiccup is that the 27 who were evaluable were deemed so because they had at least 1 CT scan after 2 months. RECIST criteria outline that an objective response seen in one visit be confirmed at a subsequent visit within no less than 4 weeks. If we acknowledge the sloppiness in this PR, there is a possibility that a couple of these responses have not been confirmed. Something to keep an eye out for.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next